Following guidance from regulatory bodies (FDA and EMA), several CVOTs have been conducted to examine the safety and tolerability of GLP-1 RAs, which include ELIXA (lixisenatide) [53], LEADER (liraglutide) [54], SUSTAIN (injectable semaglutide) [55] EXSCEL (exenatide ER) [56], HARMONY (albiglutide) [57], REWIND (dulaglutide) [58], and PIONEER 6 (oral semaglutide) [59]
Front Cell Dev Biology, 2024 ;12:1461278
Exogenous hydrogen sulfide promotes hepatocellular carcinoma cell growth by activating the STAT3-COX-2 signaling pathway
Alport syndromes: phenotypic heterogeneity of progressive hereditary nephritis
Munoz-Jimenez M, Zaarkti A, Garcia-Arnes JA, Garcia-Casares N
Digital ERP tools: App-based Exposure and Response Prevention (ERP) platforms now integrate real-time therapist coaching with between-session exercises, making evidence-based ERP more accessible outside weekly office visits